Stocks

ResMed’s stock fell over 6% due to a slowdown in organic sales growth. Despite the dip, the company reported $1.28 billion in sales, exceeding expectations. Organic sales growth decreased slightly from 11% to 10%, but earnings rose by 29% year-on-year. Concerns arose